CN Patent

CN101686973B — 应用4-氨基喹啉-3-腈治疗抗伊马替尼的白血病

Assigned to Wyeth LLC · Expires 2013-06-19 · 13y expired

What this patent protects

本发明提供了用于治疗患有对伊马替尼具有抗性的BcrAbl阳性白血病的个体的4-氨基喹啉-3-腈化合物。

USPTO Abstract

本发明提供了用于治疗患有对伊马替尼具有抗性的BcrAbl阳性白血病的个体的4-氨基喹啉-3-腈化合物。

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: CN101686973B
Jurisdiction: CN
Classification: —
Expires: 2013-06-19
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.